UNSPSC 51333504: Ocaperidone

This classification denotes an antipsychotic agent with the molecular formula C24H25FN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26HUS7139V, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2,9-dimethyl- but generally known as ocaperidone, which bears US NIH Compound Identifier 71351. European Medicines Agency schedules Ocaperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09395MIG.

UNSPSC 51333504 Ocaperidone, a Commodity code, sees minimal recent state and local procurement activity directly aligned with its nominal scope. The three recent opportunities tagged under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which represent ocaperidone specifically. The mismatch suggests that state and local procurement systems may be applying this code broadly to pharmaceutical procurement categories rather than to ocaperidone as a discrete product line. When ocaperidone procurement does occur, it appears embedded within broader pharmaceutical sourcing initiatives rather than as a standalone solicitation.

The recent opportunities originate from a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota MMCAP, serving state and local facilities across multiple states including Oregon). Seminole County issued an IFB on June 30, 2026, for naloxone and drug deactivation systems with a due date of July 26, 2023; Texas HHS posted an RFI on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs; and Minnesota MMCAP issued an RFP on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. The geographic spread includes Florida, Texas, and Minnesota with multistate reach through MMCAP. The absence of ocaperidone-specific procurement signals that this code may require monitoring for future activity rather than immediate pursuit under current market conditions.